CTLA4 inhibitormalignant melanomaimmunotherapyUniversity of Virginiaadvanced melanomacutaneous melanomatargeted therapymelanoma
…course. 43.7% received a single-agent anti-PD1, 9.1% received a CTLA4 inhibitor, and 4.0% received a targeted therapy. 34.9% had complete respo…